

1 **Evaluating the Effectiveness of International Travel Controls to Identify Monkeypox**

2 **Virus Infected Travelers**

3 **Authors**

4 Keisuke Ejima^{1,2,*†}, Yuqian Wang^{1,†}, Akira Endo^{3,4,5,†}, Hiroaki Murayama⁶, Yun Shan Goh⁷, Alex R.
5 Cook^{2,3,18}, Yong Dam Jeong^{8,9}, Shingo Iwami^{8,10,11,12,13}, Hyeongki Park⁸, Borame Sue Lee Dickens³, Shihui
6 Jin³, Jue Tao Lim¹, Conrad En Zuo Chan², Po Ying Chia^{1,2,15}, Barnaby E. Young^{1,2,14}, Yang Yang^{15,16},
7 Martin Chio^{17,18}, David Chien Lye^{1,2,14,19}, Marco Ajelli^{20,†}

8 **Affiliations**

9 ¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

10 ²National Centre for Infectious Diseases, Singapore, Singapore

11 ³Saw Swee Hock School of Public Health, National University of Singapore and National University Health
12 System, Singapore, Singapore

13 ⁴School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.

14 ⁵Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical
15 Medicine, London, UK.

16 ⁶School of Medicine, International University of Health and Welfare, Narita, Japan

17 ⁷A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research
18 (A*STAR), Singapore, Singapore.

19 ⁸interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science,
20 Nagoya University, Nagoya, Japan.

21 ⁹Department of Mathematics, Pusan National University, Busan, South Korea.

22 ¹⁰Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan.

23 ¹¹Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan.

24 ¹²NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.

25 ¹³Science Groove Inc., Fukuoka, Japan.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ¹⁴Tan Tock Seng Hospital, Singapore, Singapore

27 ¹⁵Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious
28 Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital
29 Affiliated to Southern University of Science and Technology, Shenzhen, China

30 ¹⁶National Clinical Research Center for Infectious Disease, Shenzhen, China

31 ¹⁷National Skin Centre Singapore, Singapore, Singapore

32 ¹⁸Duke-NUS Medical School, Singapore, Singapore

33 ¹⁹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

34 ²⁰Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and
35 Biostatistics, Indiana University School of Public Health-Bloomington, IN, USA.

36 * Corresponding authors: keisuke.ejima@ntu.edu.sg

37 † These authors contributed equally to this work.

38 **Keywords:** mpox, mathematical model, false negative, PCR testing, public health, quarantine, health
39 screening

40 **Abstract**

41 **Introduction:**

42 In August 2024, the World Health Organization (WHO) declared a public health emergency due to the rapid
43 spread of mpox in African and beyond. International travel controls (ITCs), such as health screening and viral
44 testing, could help avoid/delay the global spread of the monkeypox virus (MPXV), fostering preparedness and
45 response efforts. However, it is not clear whether the viral tests at immigration are sufficient to avoid
46 importation of MPXV and which samples should be used on the viral tests.

47 **Methods:**

48 We conducted a simulation study using epidemiological and viral load data to assess the effectiveness of health
49 screening and PCR testing at immigration. This provides estimates of the proportion of infected travelers
50 identified with this policy. Viral dynamics models were used to estimate false-negative rates of PCR tests with
51 different detection limits according to testing regimens at three different sites: oropharynx, saliva, and rectum.
52 We also simulated the effects of these border control methods on the recommended duration of a monitoring
53 period for travelers from mpox-affected regions, during which individuals would self-monitor for symptoms
54 and practice cautionary behavior.

55 **Results:**

56 Our results show that the combination of health screening and PCR testing of saliva swabs under an endemic
57 scenario identify only 74% of MPXV infected travelers. The use of rectal swabs combined with health
58 screening allows the identification of a marginally larger share of infected travelers (79%) compared to saliva
59 swabs. A similar identification rate could be achieved by using more sensitive PCR tests (detection limit [DL]:
60 10 copies/mL vs. 250 copies/mL used in our baseline analysis). We estimated that travelers from mpox-
61 affected areas should monitor themselves and practice precautionary behavior for 16 days.

62 **Conclusion:**

63 Health screening and PCR testing at immigration are likely to miss a significant proportion of MPXV-infected
64 travelers, thus a lengthy quarantine period would be required to prevent onward local transmission. Careful
65 consideration on other factors such as economic costs and likelihood of widespread local outbreak will need

66 to be weighed against the adoption of these measures to prevent local mpox transmission given MPXV
67 transmissibility and severity.

68 Introduction

69 Monkeypox virus (MPXV), the causative agent of mpox, has caused sporadic infections in African
70 countries for over 50 years mainly due to zoonotic spillover¹. Two clades, I and II, have been observed in
71 Central and West Africa, respectively². Clade I is associated with more severe symptoms and higher
72 mortality rates². In 2022, human-to-human transmission, mainly during sexual intercourse, of clade IIb
73 caused a global epidemic³. In September 2023, a different subtype of mpox (clade Ib) began to spread in the
74 Democratic Republic of Congo (DRC). Notably, unlike the clade IIb epidemic, which predominantly
75 impacted men who have sex with men (MSM) populations, clade Ib infection was reported in a substantial
76 number of children and commercial sex workers^{4,5}, raising significant public health concerns. In response,
77 the World Health Organization (WHO) declared the mpox outbreak a public health emergency of
78 international concern⁶. Furthermore, importations of the same subtype were identified in non-African
79 countries, including Thailand, Sweden, India, Germany, the United Kingdom, the United States, Canada and
80 Belgium. Moreover, secondary transmission was also found in the United Kingdom and Germany⁷, raising
81 concerns about its potential for further international spread.

82 Implementing effective international travel controls (ITCs) is instrumental to reduce the spread of
83 infections to other regions and is especially important when local transmission is not yet established. Common
84 ITCs include health screenings, viral testing (e.g., PCR and antigen tests), case isolation, and quarantine and/or
85 active monitoring of suspected cases⁸. Although avoiding case importation entirely may not be feasible,
86 delaying the spread may gain time to prepare resources and plan strategies to mitigate the impact of potential
87 epidemics. In particular, health screening and viral tests play a critical role in preventing the importation of
88 infected individuals. Health screening aims to detect infected individuals who are symptomatic, while viral
89 tests are used both to confirm infection in symptomatic individuals and identify pre-symptomatic and
90 asymptomatic infected individuals. Given the relatively long incubation period of mpox (approximately 8 days
91 both for the clade IIb strain responsible for the 2022 outbreak and for historical strains – clade Ia and IIa)⁹,
92 the probability of individuals traveling while pre-symptomatic is non-negligible.

93 To delay (and/or potentially avoid) an epidemic being seeded by international travelers, health
94 screenings and viral tests are often paired with quarantine periods for travelers^{10,11}. Quarantine measures vary

95 widely depending on the pathogen's severity and transmissibility and the political milieu. The implementation
96 can range from quarantine in dedicated facilities, as seen in the early stages of the COVID-19 pandemic in
97 China and other countries with effective pandemic control, to self-quarantine at home¹², or simply monitoring
98 symptoms and practicing precautionary behavior¹³. Typically, the duration of quarantine is determined by the
99 incubation period of the virus (e.g., the 95th/99th percentile). For instance, during the early phase of the
100 COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention (CDC) initially recommended a
101 14-day quarantine for individuals exposed to SARS-CoV-2¹⁴, based on epidemiological evidence suggesting
102 that the 99th percentile of the incubation period was 14 days¹⁵. However, for travelers from disease-prevalent
103 regions, such long quarantine periods may be overly conservative and suboptimal. For example, while the
104 mean incubation period of H1N1-2009 was 2.1 days¹⁶, the mean time from departure to symptom onset for
105 (infected) Japanese travelers returning from Hawaii was only 0.7 days¹⁷.

106 For mpox, several questions remain regarding international travel controls (ITCs) and quarantine
107 measures. First, it is uncertain whether viral testing bundled together with health screening at immigration is
108 sufficient to prevent the importation of MPXV. Second, with multiple sampling sites available, including
109 saliva and rectum (details provided in the next section), it is unclear which sample type should be prioritized
110 for viral testing. Third, if viral testing proves insufficient, the appropriate quarantine duration for travellers
111 from mpox-affected countries who may have been exposed remains to be determined. To address these
112 questions, we developed mathematical models informed by viral load data and epidemiological insights.

114 **Methods**

115 **False negative rates from viral dynamics model**

116 Critical to determining the effectiveness of border measures is the false negative rate of viral tests,
117 including PCR tests, which is influenced by the viral load and the ability of the test to detect the virus
118 (detection limit). Since the viral load varies throughout the course of an infection, increasing initially,
119 reaching a peak, and then declining, the false negative rate also changes over time¹⁵. In a previous study, we
120 estimated false negative rates for PCR tests for SARS-CoV-2 using a mathematical model of within-host
121 viral dynamics, considering the timing of tests and different detection limits¹⁸. Here we adapted the same
122 approach to estimate the false-negative rate of PCR tests for MPXV.

124 ***MPXV viral load data***

125 To parameterize the viral dynamics model, we analyzed two prospective longitudinal cohort studies.
126 The first cohort enrolled 77 men with acute mpox infections (clade IIb) hospitalized in Shenzhen, China,
127 between June 9 and November 5, 2023¹⁹. Participants were followed up to 21 days after symptom onset.
128 Samples were collected every 2-3 days from various sites, including skin lesions, rectum, saliva,
129 oropharynx, urine, and plasma. The second cohort enrolled 25 individuals who had high-risk contact with
130 mpox infected patients in Antwerp, Belgium, between June 24 and July 31, 2022²⁰. Participants were
131 followed up for a maximum of 21 ± 2 days after inclusion, while infected participants were monitored until
132 they tested MPXV-PCR positive with typical mpox symptom onset and then referred to routine clinical care.
133 During weekly follow-up visits, blood, saliva, oropharyngeal swabs, genital swabs, anorectal swabs, and
134 skin lesion swabs were collected. Additionally, anorectal swabs, genital swabs, and saliva were also
135 collected through daily self-sampling. PCR sensitivity was higher with oropharynx, saliva, rectum, and skin
136 lesions (>70%), while PCR sensitivity was lower with urine, serum, genital swabs and plasma samples
137 (<50%). Hence, we have focused our analysis on samples with higher PCR sensitivity (oropharynx, saliva,
138 and rectum) for ITC purposes. It is worth noting that we have excluded the skin lesion data in the analysis,
139 as PCR testing on skin lesions can only be conducted after lesions are visible. Therefore, relying on skin
140 lesions for PCR testing at immigration to identify infected individuals is moot. Quantitative reverse

141 transcription PCR (qRT-PCR) was used to measure cycle threshold (Ct) values. To convert the Ct value to
142 viral load, we applied the following equation: $Ct = -3.611(\log_{10} RNA) + 41.388$ as described in the
143 paper¹⁹. Ct values > 40 (i.e., $< 10^3$ copies/mL for viral load) are considered negative.

144 145 *Viral dynamics model and fitting*

146 To characterize the MPVX viral dynamics, we used the following system of ordinary differential
147 equations, which accounts for the fundamental biological process of the infection within a host, including
148 viral replication and elimination due to immune response:

$$\begin{aligned} 149 \quad \frac{dT(t)}{dt} &= - \overbrace{\beta T(t)V(t)}^{\text{infection of uninfected cells}}, \\ 150 \quad \frac{dI(t)}{dt} &= \overbrace{\beta T(t)V(t)}^{\text{infection of uninfected cells}} - \overbrace{\delta I(t)}^{\text{removal of infected cells}}, \\ 151 \quad \frac{dV(t)}{dt} &= \overbrace{pI(t)}^{\text{production of viruses}} - \overbrace{cV(t)}^{\text{removal of viruses}}, \end{aligned}$$

152 where the variables $T(t)$, $I(t)$, and $V(t)$ represent the number of uninfected target cells, number of infected
153 target cells, and amount of virus at t days after symptom onset, respectively. These represent the infection of
154 uninfected cells at rate $\beta T(t)V(t)$ and the removal of infected cells at rate $\delta I(t)$ cells per day, and the
155 production of virus at rate $pI(t)$ and the removal of virus at rate $cV(t)$ viral units per day. Note that we use
156 days after symptom onset as the time scale. The model parameters β , δ , p , and c represent the rate of virus
157 infection, death rate of infected cells, (per cell) viral production rate, and (per capita) clearance rate of the
158 virus, respectively. Under the quasi-steady-state assumption, the model is reduced to a two-dimensional
159 model as follows:

$$\begin{aligned} 160 \quad \frac{dg(t)}{dt} &= -\beta g(t)V(t), \\ 161 \quad \frac{dV(t)}{dt} &= \gamma g(t)V(t) - \delta V(t), \end{aligned}$$

162 where $g(t)$ is the fraction of uninfected target cell population at day t to that at day 0 (i.e., $g(0) = 1$), and
163 $V(t)$ is the amount of virus at day t (copies/mL), respectively. Note that time 0 corresponds to the day of

164 symptom onset. Details on the transformation of this model are reported in the reference²¹. The quasi-
165 steady-state assumption is generally reasonable for most viruses causing acute infectious disease because the
166 clearance rate of virus (c) is typically much larger than the death rate of the infected cells (δ) as evidenced
167 by *in vivo* observations²¹⁻²³. Thus, we estimated the four parameters: β , γ , δ , and $V(0)$ (viral load at the day
168 of symptom onset). We fit the viral dynamics model to the viral load data collected from the three different
169 sites (rectum, saliva, and oropharynx) independently using a non-linear mixed effect model.

170 The nonlinear mixed-effects model incorporates fixed effects and random effects accounting for
171 inter-site variability in viral dynamics. Specifically, the parameter for site k , $\theta_k (= \theta \times e^{\pi_k})$, is represented
172 by the fixed effect, θ , and the random effect, π_k , is assumed to follow the Gaussian distribution with mean 0
173 and standard deviation Ω . The fixed effect (population parameter) and random effect were estimated by
174 using the stochastic approximation expectation-maximization (EM) algorithm and empirical Bayes' method,
175 respectively. We chose these methods because the EM algorithm is well-suited for estimating population-
176 level parameters in the presence of latent variables, whereas the empirical Bayes allows us to efficiently
177 estimate inter-site-level variations by using prior information. Using estimated parameters and a Markov
178 Chain Monte Carlo algorithm, we obtained the conditional distribution of model parameters for each site.
179 Left censoring was considered based on the lower limit of detection (Ct values < 40). Monolix 2023R1
180 (<https://www.lixoft.com>) was used for viral dynamics model fitting.

181 ***Simulation analysis to estimate false negative rates over time***

182 We repeatedly randomly resampled a parameter set for individual i at site k (i.e., β_{ik} , γ_{ik} , δ_{ik} , and
183 $V(0)_{ik}$) from the estimated posterior distributions, and ran the viral dynamics model. The viral load obtained
184 by running the viral dynamics model is considered as the “true” viral load, $V_{ik}(t)$. However, PCR test
185 results are influenced by measurement error. To account for this, we added measurement error to the true
186 viral load to simulate *measured viral load*, $\hat{V}_{ik}(t)$, whereby $\log_{10} \hat{V}_{ik}(t) = \log_{10} V_{ik}(t) + \varepsilon_{ik}$,
187 $\varepsilon_{ik} \sim N(0, \sigma_k^2)$ ^{24,25}. As the time scale of the viral dynamics model is days after symptom onset, we corrected
188 the time scale to time after infection by adding incubation period, η , drawn from the incubation period
189 distribution obtained from the meta-analysis⁹. That says, $V_{ik}(\tau) = V_{ik}(t + \eta)$, $\eta \sim \log N(1.92, 0.60)$

191 (mean=8.1, 95th percentile=18), where τ is the infection age (i.e., the time which has elapsed since
192 infection). The error distribution is obtained by fitting a normal distribution to the residuals (i.e., the
193 difference between the common logarithms of the true viral load and the measured viral load). We repeated
194 this process 10,000 times to create the viral-load distribution over time. The false-negative rate at site k at
195 infection age τ is computed as the proportion of cases with a viral load below the detection limit: $p_k(\tau) =$
196 $\sum_{i=1}^{1000} I(\hat{V}_{ik}(\tau) < DL)/1000$, where DL is the detection limit, and I is the identity function. We used 250
197 copies/mL as the detection limit of PCR tests²⁶. As a sensitivity analysis, we performed the same simulation
198 using different detection limits, namely 10 and 1,000 copies/mL.

200 **Detection rates by health screening and PCR tests and post-entry incubation periods for travelers**

201 To assess the impact of health screenings and PCR tests, we examined a population of individuals
202 infected during travel in mpox-affected countries and moving to non-mpox-affected countries. Upon arrival
203 in non-mpox-affected countries, the time elapsed since infection, referred to as the infection age (τ),
204 represents the duration between the date of infection and the date of arrival at the travel destination.
205 Assuming that the mpox cases still were exponentially increasing at the country of origin at a growth rate r
206 and travelers are exposed proportionally to the number of the cases, the number of infected (traveling)
207 individuals with infection age τ at immigration is described as follows: $j(\tau) = j_0 \exp(-r\tau)$, where j_0 is a
208 constant number representing those at infection age $\tau = 0$ ($j(0) = j_0$). Given that health screenings at
209 immigration detect individuals with symptoms, we aim to use PCR tests to identify asymptomatic
210 individuals at the time of entry. These individuals are modeled as being in the early stages of infection,
211 where the infection age τ is below the threshold for symptom manifestation. The probability of detecting an
212 asymptomatic individual with a PCR test is described as a function of viral load dynamics over τ , modeled
213 as $j_{pre}(\tau) = j_0 \exp(-r\tau)L(\tau)$, where $L(\tau)$ is the survival function of symptom development by infection
214 age τ . The survival function of symptom development $L(\tau)$ can be computed from the probability density
215 function of incubation period, $f(\tau)$, as $L(\tau) = 1 - \int_0^\tau f(u)du$. The number of pre-symptomatic individuals
216 who test negative for mpox on PCR tests conducted at immigration is represented by $j_{pre,neg}(\tau) =$

217 $j_0 \exp(-r\tau)L(\tau)p(\tau)$, where $p(\tau)$ is the false-negative rate of PCR tests at infection age τ . The proportion
 218 of infected travelers who develop symptoms and are subsequently identified by the health screenings at
 219 immigration (including those who cancelled travel due to symptoms) can be modeled as $H = 1 -$

220 $\frac{\int_0^\infty j_{pre}(u)du}{\int_0^\infty j(u)du} = 1 - \frac{\int_0^\infty \exp(-ru)L(u)du}{\int_0^\infty \exp(-ru)du}$. This assumes that the health screenings detect all symptomatic mpxo

221 cases. The proportion of infected travelers identified through PCR testing can be modeled as $T =$

222 $\frac{\int_0^\infty j_{pre}(u) - j_{pre,neg}(u)du}{\int_0^\infty j(u)du} = \frac{\int_0^\infty \exp(-ru)L(u)(1-p(u))du}{\int_0^\infty \exp(-ru)du}$. Note that j_0 is cancelled in the derivation process of H

223 and T .

224 The quarantine period can be determined based on the incubation period, assuming that the time of
 225 exposure is known – typically the 95th percentile of the incubation period distribution²⁷. However, in this
 226 study, we assume that the timing of exposure is not known and only the timing of entrance to the country is
 227 known. Therefore, the quarantine period begins upon entry into the country. To determine the appropriate
 228 length, we estimated the remaining incubation period for pre-symptomatic individuals at immigration (time
 229 from immigration to symptom onset, hereafter referred to as *post-entry incubation period*). The 95th, 80th,
 230 and 70th percentiles of this post-entry incubation period were used to define the quarantine period. We
 231 emphasize here that quarantine refers to self-monitoring for mpxo symptoms and practicing precautionary
 232 behavior (e.g., abstinence).

233 From the mathematical standpoint, we set the time after immigration, s , as a time scale. Given a
 234 maximum travel duration of k days, the number of individuals that developed symptoms at time s , $i(s)$, can
 235 be modeled as

236
$$i(s) = \int_0^k f(s+u) \frac{j_{pre,neg}(u)}{L(u)} du = \int_0^k f(s+u) j_0 \exp(-ru) p(u) du,$$

237 because those who are presymptomatic and test-negative on mpxo PCR test at immigration with infection
 238 age u , $j_{pre,neg}(u)$, have already survived (i.e., did not develop symptoms) for u days at the time of

239 immigration, $L(u)$, and develop symptoms s days after immigration, when their infection age is $s+u$. In

240 other words, the distribution of a presymptomatic and test-negative infected traveler's time from

241 immigration to symptom onset, s , conditional to time from exposure to immigration being u and the absence

of symptoms by immigration is $f(s + u)/L(u)$. As $i(s)$ is a number, it can be normalized to be a probability density function of the post-entry incubation period as $i(s)/\int_0^\infty i(u)du$. Note that j_0 is cancelled after normalization. We also conducted sensitivity analyses under an epidemic scenario assuming $R_0 = 1.5$ ²⁸. **Supplemental Table 1** summarizes the variables used in this study. All epidemiological parameters except false-negative rate (obtained by fitting the viral dynamics model to the viral load data) are obtained from literature on clade IIb except incubation period (from clade Ia, IIa, and IIb) (**Supplemental Table 2**).

Result

Time-and-site-dependent false-negative rates

The viral load curve for each of the four sites shows a similar trend, but remarkable differences (**Figure 1**). The peak viral load occurred at 5 days after symptom onset for rectum and oropharynx samples and 6 days for saliva samples. Peak viral load levels from the rectum samples were the highest levels ($10^{6.8}$ copies/mL), around ten-fold higher than from saliva samples ($10^{5.7}$ copies/mL), which in turn was around ten-fold higher than from the oropharynx samples ($10^{4.8}$ copies/mL). MPXV remained detectable for varying durations: 19 days for rectum, 18 days for saliva, and 14 days for oropharynx. We emphasize that the length of viral shedding may exceed that of infectiousness, as the infectiousness threshold for mpox, $10^{6.5}$ copies/mL²⁹, is higher than the detection limit. A comparison between the simulated viral load curves and the observed data for each infected individual is shown in **Supplemental Figure 1**, showing good overall concordance to the theoretical model. We also compared the estimated parameter values from the different sites (**Supplemental Figure 2**) and found a moderate correlation in the viral dynamic parameters of oropharynx and saliva. Estimated model parameters are reported in **Supplemental Table 3**.

The estimated viral dynamics allowed us to estimate false negative rate over time for various detection limits: 10, 250, and 1000 copies/mL (**Figure 2**). Using 250 copies/mL as the reference detection limit, we observed that the false negative rate is initially at 82%, 89%, 91% for rectum, saliva, and oropharynx, respectively and then decreases towards the viral load peak and subsequently increases as the viral loads fall. The lowest false negative rates were 15%, 25%, and 34% for rectum, saliva, and oropharynx,

269 respectively, implying that even with the ideal timing, a high proportion of infections would be missed from
270 border screening. The high false negative rate for oropharynx is explained by the relatively low mean viral
271 load compared with saliva. Similar trends were observed for other detection limits, with higher detection
272 limits generally associated with higher false negative rates.

273 Given the ease of saliva sampling, we selected saliva for PCR testing at immigration as a primary
274 analysis. Rectal and oropharyngeal swabs were considered for sensitivity analyses.

276 **Effectiveness of health screenings and PCR tests in identifying infected travelers**

277 Assuming an endemic situation at the source, health screenings at immigration will successfully
278 identify 62% of infected individuals (**Figure 3**). When PCR tests are conducted on saliva samples from all
279 pre-symptomatic individuals, an additional 12% of MPXV infected individuals will be identified (detection
280 limit: 250 copies/mL). Assuming a more sensitive detection limit of 10 copies/mL, the detection rate would
281 increase to 16%. A different fraction of MPXV infected travelers would be identified if rectal or
282 oropharyngeal swabs were to be collected: 17% and 11%, respectively, assuming a detection limit of 250
283 copies/mL. As the mean incubation period is 8.1 days and only those who are not symptomatic could be
284 identified by PCR tests at the border, the lower false-negative rate before the symptom onset yields to higher
285 detection rate. Under the assumption of a growing epidemic (with R_0 of 1.5) at the source, health screenings
286 at immigration would identify 51% of infected individuals (**Supplemental Figure 3**). 20, 14, and 12% more
287 cases would be identified by PCR tests on rectal, saliva, and oropharyngeal swabs, respectively.

288 **Length of the quarantine period**

289 We defined quarantine periods based on the 95th, 80th, and 70th percentiles of the incubation period
290 and post-entry incubation period distribution, as illustrated in **Figure 4**. The 95th percentile is commonly
291 used, allowing for a 5% risk of ending quarantine before symptom development. Using lower percentiles
292 (70th or 80th) can reduce the quarantine period, but increases the risk of infected individuals being released
293 prematurely while still being pre-symptomatic.

294 Assuming endemicity at the source, when solely relying on the 95th percentile of the incubation
295 period, a quarantine of 18 days is recommended. However, using the 80th or 70th percentiles reduces the

296 quarantine period to 11 and 9 days, respectively. If health screening is implemented at immigration, the 95th
297 percentile of the post-entry incubation period is 15.5 days, suggesting a 2.5-day reduction in quarantine
298 period compared to using the incubation period alone. Conversely, when PCR tests (DL=250 copies/mL) are
299 conducted, the 95th percentile of the post-entry incubation period increases slightly, suggesting a quarantine
300 period of 15.6 days. Even when assuming epidemic situation, we confirmed the quarantine period (i.e., the
301 95th percentile of the incubation period) is about 15.7 days with health screening and PCR tests.

302 **Supplemental Figure 5** illustrates the incubation period distribution and post-entry incubation period for
303 different samples with different detection limits under epidemic and endemic situations.

304 Similar results were observed in sensitivity analyses that varied the percentile used to determine the
305 quarantine period (70th and 80th percentiles) and considered different swab types for PCR testing at
306 immigration (rectal and oropharyngeal swabs).

308 Discussion

309 In response to the Public Health Emergency of International Concern declared by the WHO and the
310 identification of MPXV outside the African continent, public health authorities and other major stakeholders
311 are evaluating the possibility of implementing immigration control measures. For example, on August 23,
312 2024, Singapore Ministry of Health has implemented health screenings, including temperature checks and
313 visual assessments, at international airports and seaports for travelers and crew arriving from mpox-affected
314 regions³⁰.

315 To evaluate the effectiveness of immigration control measures, we developed a mathematical model
316 to assess the proportion of infected travelers identified through health screenings and PCR testing. We found
317 that a combination of health screenings and PCR testing of saliva at immigration can identify 74% of the
318 MPXV infected travelers. Even considering more sensitive tests (i.e., 10 copies/mL as the detection limit) or
319 other swab sites (i.e., oropharynx and rectum samples) would not allow the identification of about 20% of
320 MPXV infected travelers. Should public health authorities aim at fully preventing onward local transmission,
321 combining health screening and PCR testing would need to be supplemented by a quarantine period for
322 travelers coming from mpox-affected areas. Our findings indicate that a quarantine duration of 16 days would

323 be required. We also provide time-varying false negative rate estimates for various detection limits, offering
324 critical insights into the effectiveness of deploying different test types as they become available.

325 This study has some limitations. First, due to the limited clinical and epidemiological information
326 available for clade Ib, most parameters were based on clade IIB, which caused the 2022 outbreak. As more
327 relevant data becomes available for clade Ib it would be advantageous to update this modeling analysis.
328 Second, we did not fully account for fully asymptomatic infections in our analysis. Serological surveys and
329 screening tests have provided evidence of asymptomatic MPXV clade IIB infections³¹⁻³³. Further research is
330 warranted to investigate the role of asymptomatic infection in MPXV transmission. Third, we only modelled
331 quarantine of individuals who may have been infected; therefore, we have not argued how to treat confirmed
332 cases such as medical treatment and isolation (to avoid further transmission). Fourth, our analysis considered
333 the time elapsed between exposure and arrival at the destination country. On one hand, this enables us to
334 obtain more realistic estimation of the post-entry incubation period; on the other hand, this means that our
335 findings should be revised if the MPXV affected areas start to show larger or lower rates of local
336 transmission. Fifth, we did not consider specificity of health screening and PCR tests. In general, the
337 specificity of PCR tests is high (and considered as the gold standard test method)³⁴; however, given that
338 mpox can present with typical symptoms (such as fever), high specificity (i.e., to minimize the risk of false
339 positives) is important from an operational perspective in health screening.

340 It is important to stress that our study does not discuss whether or under which circumstances ITCs are
341 recommended; instead, it provides quantitative estimates of the effectiveness of a combination of health
342 screenings and PCR tests at immigration (approximately 75% of infected travelers) and of quarantine duration
343 after arrival (approximately 2 weeks). The decision to implement public health interventions is for local
344 authorities to make based on a wider range of considerations that go beyond the effectiveness of ITCs and
345 quarantine, such as disease severity, likelihood of a widespread local outbreak, ability to control local spread
346 through other measures, economic costs, strategy feasibility, among others. Furthermore, these factors may
347 evolve over time. For example, Murayama and Asakura et al.³⁵ suggested that clade Ib acquired the capacity
348 to be sexually transmitted, which is a possible explanation for the increased outbreak potential. For this reason,
349 careful thought should be taken on the right degree of surveillance at the border as the epidemiology changes.

350 References

- 351 1 Van Dijk, C. *et al.* Emergence of mpox in the post-smallpox era—a narrative review on mpox
352 epidemiology. *Clinical Microbiology and Infection* **29**, 1487-1492 (2023).
353 <https://doi.org/10.1016/j.cmi.2023.08.008>
- 354 2 Bunge, E. M. *et al.* The changing epidemiology of human monkeypox—A potential threat? A
355 systematic review. *PLOS Neglected Tropical Diseases* **16**, e0010141 (2022).
356 <https://doi.org/10.1371/journal.pntd.0010141>
- 357 3 World Health Organization. *Fifth Meeting of the International Health Regulations (2005) (IHR)*
358 *Emergency Committee on the Multi-Country Outbreak of mpox (monkeypox)*, <Fifth Meeting of the
359 International Health Regulations (2005) (IHR) Emergency Committee on the Multi-Country
360 Outbreak of mpox (monkeypox)> (
- 361 4 Boisson-Walsh, A. Escalating mpox epidemic in DR Congo. *The Lancet Infectious Diseases* **24**,
362 e487 (2024). [https://doi.org/10.1016/S1473-3099\(24\)00446-8](https://doi.org/10.1016/S1473-3099(24)00446-8)
- 363 5 Adebisi, Y. A., Ezema, S. M., Bolarinwa, O., Bassey, A. E. & Ogunkola, I. O. Sex Workers and the
364 Mpox Response in Africa. *J Infect Dis* (2024). <https://doi.org/10.1093/infdis/jiae435>
- 365 6 WHO Director-General declares mpox outbreak a public health emergency of international concern,
366 <[https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-](https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern)
367 [public-health-emergency-of-international-concern](https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern)> (
- 368 7 European Centre for Disease Prevention and Control, *Communicable disease threats report, 14-20*
369 *December 2024, week 51*, <[https://www.ecdc.europa.eu/en/publications-data/communicable-disease-](https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-14-20-december-2024-week-51)
370 [threats-report-14-20-december-2024-week-51](https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-14-20-december-2024-week-51)> (
- 371 8 Grépin, K. A., Aston, J. & Burns, J. Effectiveness of international border control measures during the
372 COVID-19 pandemic: a narrative synthesis of published systematic reviews. *Philos Trans A Math*
373 *Phys Eng Sci* **381**, 20230134 (2023). <https://doi.org/10.1098/rsta.2023.0134>
- 374 9 Ponce, L. *et al.* Incubation Period and Serial Interval of Mpox in 2022 Global Outbreak Compared
375 with Historical Estimates. *Emerg Infect Dis* **30**, 1173-1181 (2024).
376 <https://doi.org/10.3201/eid3006.231095>
- 377 10 Quilty, B. J. *et al.* Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling
378 study. *The Lancet Public Health* **6**, e175-e183 (2021). [https://doi.org/10.1016/S2468-](https://doi.org/10.1016/S2468-2667(20)30308-X)
379 [2667\(20\)30308-X](https://doi.org/10.1016/S2468-2667(20)30308-X)
- 380 11 Wells, C. R. *et al.* Optimal COVID-19 quarantine and testing strategies. *Nature communications* **12**,
381 356 (2021). <https://doi.org/10.1038/s41467-020-20742-8>
- 382 12 Jin, Y., Sun, T., Zheng, P. & An, J. Mass quarantine and mental health during COVID-19: A meta-
383 analysis. *Journal of Affective Disorders* **295**, 1335-1346 (2021).
384 <https://doi.org/10.1016/j.jad.2021.08.067>
- 385 13 World Health Organization. *COVID-19: quarantine and self-monitoring*,
386 <[https://www.who.int/westernpacific/emergencies/covid-19/information/quarantine-and-self-](https://www.who.int/westernpacific/emergencies/covid-19/information/quarantine-and-self-monitoring)
387 [monitoring](https://www.who.int/westernpacific/emergencies/covid-19/information/quarantine-and-self-monitoring)> (
- 388 14 *Infection Control Guidance: SARS-CoV-2*, <[https://www.cdc.gov/covid/hcp/infection-](https://www.cdc.gov/covid/hcp/infection-control/index.html)
389 [control/index.html](https://www.cdc.gov/covid/hcp/infection-control/index.html)> (
- 390 15 Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly
391 Reported Confirmed Cases: Estimation and Application. *Annals of internal medicine* **172**, 577-582
392 (2020). <https://doi.org/10.7326/m20-0504>
- 393 16 Ghani, A. *et al.* The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom.
394 *PLoS Curr* **1**, Rrn1130 (2009). <https://doi.org/10.1371/currents.RRN1130>
- 395 17 Nishiura, H. & Inaba, H. Estimation of the incubation period of influenza A (H1N1-2009) among
396 imported cases: Addressing censoring using outbreak data at the origin of importation. *Journal of*
397 *theoretical biology* **272**, 123-130 (2011). <https://doi.org/10.1016/j.jtbi.2010.12.017>
- 398 18 Ejima, K. *et al.* Time variation in the probability of failing to detect a case of polymerase chain
399 reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. *J R Soc Interface* **18**,
400 20200947 (2021). <https://doi.org/10.1098/rsif.2020.0947>

- 401 19 Yang, Y. *et al.* Longitudinal viral shedding and antibody response characteristics of men with acute
402 infection of monkeypox virus: a prospective cohort study. *Nature communications* **15**, 4488 (2024).
403 <https://doi.org/10.1038/s41467-024-48754-8>
- 404 20 Brosius, I. *et al.* Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort
405 study. *Journal of Medical Virology* **95**, e28769 (2023).
406 [https://doi.org:https://doi.org/10.1002/jmv.28769](https://doi.org/https://doi.org/10.1002/jmv.28769)
- 407 21 Ikeda, H. *et al.* Quantifying the effect of Vpu on the promotion of HIV-1 replication in the
408 humanized mouse model. *Retrovirology* **13**, 23 (2016). <https://doi.org/10.1186/s12977-016-0252-2>
- 409 22 Martyushev, A., Nakaoka, S., Sato, K., Noda, T. & Iwami, S. Modelling Ebola virus dynamics:
410 Implications for therapy. *Antiviral Res* **135**, 62-73 (2016).
411 <https://doi.org/10.1016/j.antiviral.2016.10.004>
- 412 23 Nowak, M. A. & May, R. M. *Virus dynamics : mathematical principles of immunology and virology*.
413 (Oxford University Press, 2000).
- 414 24 Jeong, Y. D. *et al.* Revisiting the guidelines for ending isolation for COVID-19 patients. *eLife* **10**,
415 e69340 (2021). <https://doi.org/10.7554/eLife.69340>
- 416 25 Jeong, Y. D. *et al.* Designing isolation guidelines for COVID-19 patients with rapid antigen tests.
417 *Nat Commun* **13**, 4910 (2022). <https://doi.org/10.1038/s41467-022-32663-9>
- 418 26 Allan-Blitz, L.-T. *et al.* Laboratory validation and clinical performance of a saliva-based test for
419 monkeypox virus. *Journal of Medical Virology* **95**, e28191 (2023).
420 [https://doi.org:https://doi.org/10.1002/jmv.28191](https://doi.org/https://doi.org/10.1002/jmv.28191)
- 421 27 Nishiura, H. Determination of the appropriate quarantine period following smallpox exposure: An
422 objective approach using the incubation period distribution. *International Journal of Hygiene and*
423 *Environmental Health* **212**, 97-104 (2009). [https://doi.org:https://doi.org/10.1016/j.ijheh.2007.10.003](https://doi.org/https://doi.org/10.1016/j.ijheh.2007.10.003)
- 424 28 Kwok, K. O., Wei, W. I., Tang, A., Wong, S. Y. S. & Tang, J. W. Estimation of local transmissibility
425 in the early phase of monkeypox epidemic in 2022. *Clin Microbiol Infect* **28**, 1653.e1651-
426 1653.e1653 (2022). <https://doi.org/10.1016/j.cmi.2022.06.025>
- 427 29 Suñer, C. *et al.* Viral dynamics in patients with monkeypox infection: a prospective cohort study in
428 Spain. *The Lancet. Infectious diseases* **23**, 445-453 (2023). [https://doi.org/10.1016/s1473-
429 3099\(22\)00794-0](https://doi.org/10.1016/s1473-3099(22)00794-0)
- 430 30 Ministry of Helath, Singapore, Update On Public Health Preparedness Measures for Mpx Clade I,
431 <[https://www.moh.gov.sg/news-highlights/details/update-on-public-health-preparedness-measures-
432 for-mpox-clade-i](https://www.moh.gov.sg/news-highlights/details/update-on-public-health-preparedness-measures-for-mpox-clade-i)> (
- 433 31 De Baetselier, I. *et al.* Retrospective detection of asymptomatic monkeypox virus infections among
434 male sexual health clinic attendees in Belgium. *Nature medicine* **28**, 2288-2292 (2022).
435 <https://doi.org/10.1038/s41591-022-02004-w>
- 436 32 Agustí, C. *et al.* Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or
437 with unrecognized Mpx, in Spain. *Nature communications* **14**, 5998 (2023).
438 <https://doi.org/10.1038/s41467-023-40490-9>
- 439 33 Ferré, V. M. *et al.* Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men
440 Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France.
441 *Annals of internal medicine* **175**, 1491-1492 (2022). <https://doi.org/10.7326/m22-2183>
- 442 34 Sabat, J. *et al.* A comparison of SARS-CoV-2 rapid antigen testing with realtime RT-PCR among
443 symptomatic and asymptomatic individuals. *BMC Infect Dis* **23**, 87 (2023).
444 <https://doi.org/10.1186/s12879-022-07969-0>
- 445 35 Murayama, H. *et al.* Roles of community and sexual contacts as drivers of clade I mpox outbreaks.
446 *medRxiv*, 2024.2010.2015.24315554 (2024). <https://doi.org/10.1101/2024.10.15.24315554>
- 447

448 **Data availability**

449 The data that support the findings of this study are available from the corresponding authors on request.

450

451 **Code availability**

452 All analyses were performed with the statistical computing software R (version 4.3.3) ([https://www.r-](https://www.r-project.org/)
453 [project.org/](https://www.r-project.org/)). The analysis using nonlinear mixed-effects modeling was performed on Monolix 2023R1
454 (<https://www.lixoft.com/>). The study's supporting codes can be found on Github at
455 <https://github.com/SherryYuqianWang/Mpox>.

456

457 **Acknowledgments**

458 This study was supported in part by the Ministry of Education, Singapore, under its Academic Research
459 Fund Tier 1 Seed Award (RLMOE100201900000001), a Lee Kong Chian School of Medicine startup grant
460 (LKCmedicine-SUG, #022487-00001), and JST, PRESTO (JPMJPR23R3) (to KE). AE is supported by
461 Japan Society for the Promotion of Science (JP22K17329) and JST (JPMJPR22R3).

462

463 **Author contributions**

464 Conceived and designed the study: KE, MA. Obtained and analyzed the data: KE, YW, YY, HP. Wrote the
465 paper: KE, YW, AE, HM, YSG, ARC, YDJ, SI, HP, BSLD, SJ, JTL, CEZC, PYC, BEY, YY, MC, DCL,
466 and MA. All authors read and approved the final manuscript.


467

468 **Competing interest statement**

469 All authors declare that they have no competing interests.

470 Figures

471 **Figure 1: Estimated viral load over time.**



472

473

The thick lines are the estimated mean viral load trajectories for the three sites: rectum, saliva, and

474

oropharynx. The shaded regions correspond to 50% and 95% CIs. The red horizontal line corresponds to the

475


detection limit in the original study¹⁹ (10^3 copies/mL).

476

477

478

Figure 2: False-negative rates of PCR tests on rectum, saliva, and oropharynx



479

480


The false-negative rates of PCR tests were computed for rectum, saliva, and oropharynx over time. The

481

different types of lines correspond to different detection limits (10, 250, 1000 copies/mL).

482


483 **Figure 3: Effectiveness of health screening and PCR tests on identifying infected travelers under**
 484 **endemic situation.**



485
 486 Among travelers infected in mpox-affected countries, a portion is detected through screenings based on
 487 symptom presence (dark blue) and PCR tests (light blue) conducted at immigration. We considered four
 488 scenarios: health screening only (HS), health screening combined with PCR testing at a detection limit of 10
 489 copies/mL (HS+PCR1), 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3). For PCR testing, we
 490 simulated the use of rectum, saliva, or oropharyngeal sample assuming endemic situation.

491

492 **Figure 4: Quarantine period under health screening and PCR tests at immigration assuming endemic**
493 **situation.**




494
495 Quarantine period was computed as 70th, 80th, and 95th percentiles of (post-entry) incubation period
496 distribution. We considered four scenarios: no health screening and PCR tests (No tests), health screening
497 only (HS), health screening combined with PCR testing at a detection limit of 10 copies/mL (HS+PCR1),
498 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3) under endemic situation. For PCR testing, we
499 simulated the use of rectum, saliva, or oropharyngeal sample assuming endemic situation.

500
501

502 **Supplemental Figures**

503 **Supplemental Figure 1: Estimated viral load curve for each infected individual**

504 The thick lines are the viral load trajectory drawn based on the best-fit parameter set for the three sites:
505 rectum (orange), saliva (purple), and oropharynx (pink) for individuals with detectable viral load. The
506 circles correspond to observed viral load. The viral load below the detection limit (10^3 copies/mL) is shown
507 by open circles.




508

509


510
511

Supplemental Figure 2: Rank correlation between individual parameter of the three sites




512
513

514 **Supplemental Figure 3: Effectiveness of health screening and PCR tests on identifying infected travelers**
 515 **under epidemic situation**



516
 517 Among travelers infected in mpox-affected countries, a portion is detected through screenings based on
 518 symptom presence (dark blue) and PCR tests (light blue) conducted at immigration. We considered four
 519 scenarios: health screening only (HS), health screening combined with PCR testing at a detection limit of 10
 520 copies/mL (HS+PCR1), 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3). For PCR testing, we
 521 simulated the use of rectum, saliva, or oropharyngeal sample under epidemic situation.

522
 523 **Supplemental Figure 4: Quarantine period under health screening and PCR tests at immigration**
 524 **assuming epidemic situation.**




525
 526 Quarantine period was computed as 70th, 80th, and 95th percentiles of (post-entry) incubation period
 527 distribution. We considered four scenarios: no health screening and PCR tests (No tests), health screening

528 only (HS), health screening combined with PCR testing at a detection limit of 10 copies/mL (HS+PCR1),
529 250 copies/mL (HS+PCR2), or 1000 copies/mL (HS+PCR3) under epidemic situation. For PCR testing, we
530 simulated the use of rectum, saliva, or oropharyngeal sample assuming epidemic situation.

531

532 **Supplemental Figure 5: Post-entry incubation period distributions**

533 The incubation period distribution and the post-entry incubation distributions. We assumed PCR tests with
534 different detection limits are performed at immigration (10, 250, and 1000 copies/mL). We performed the
535 same simulation assuming PCR tests are performed on rectum, saliva, or oropharyngeal sample assuming
536 epidemic and endemic situation.



540 **Supplemental Tables**

Supplemental Table 1. Variables related to infected individuals

Variables	Description
$j(\tau)$	The number of infected travelers who reach countries without mpox outbreaks at infection age, τ
$j_{pre}(\tau)$	Among $j(\tau)$, the number of infected travelers who are not symptomatic (pre-symptomatic)
$j_{pre,neg}(\tau)$	Among $j(\tau)$, the number of individuals who are test negative by PCR tests performed at immigration
$i(s)$	The number of infected travelers who develop symptom at time s
$p(\tau)$	False-negative rate of PCR tests

541

Supplemental Table 2. Epidemiological parameters for mpox

Parameter	Description	Value	Ref
$L(\tau)$	The proportion of infected travelers still presymptomatic (incubating) at infection age τ : $1 - \int_0^\tau f(s) ds$	Estimated from $f(\tau)$	-
$f(\tau)$	The probability density function of incubation period	lognorm(1.92,0.60) (mean=8.1, 95%ile=18)	9
R_0	Basic reproduction number	1.5	28
T_g	Mean generation time	8.7	9
r	Epidemic growth rate: $(R_0 - 1)/T_g$	Estimated from R_0 and T_g	-
k	The maximum duration of travel (days)	21	assumption

542

Supplemental Table 3. Estimated model parameters for the viral dynamics model

Parameter ^a	Maximum rate constant for viral replication	Rate constant for virus infection	Death rate of infected cells	Viral load at symptom onset
Symbol	γ	β	δ	$V(0)$
Unit	day ⁻¹	(copies/mL) ⁻¹ day ⁻¹	day ⁻¹	copies/mL
Rectum		2.71×10^{-8} (2.44×10^{-8})	0.88 (0.27)	1.08×10^4 (9.61×10^6)
Saliva	3.19 (0.66)	2.0×10^{-7} (2.4×10^{-6})	0.85 (0.25)	1.37×10^2 (3.26×10^8)
Oropharynx		2.15×10^{-6} (6.3×10^{-6})	0.89 (0.25)	4.71×10^1 (1.3×10^5)

Standard deviation of the residual error^b

1.4 (0.09)

^anumbers in parentheses are the standard deviation

^bnormal distributions were assumed with mean 0

543

Supplemental Table 4. Mean, median, variance of post-entry incubation period distributions (days)

	Mean	Median	Variance
HS	5.8	4.5	23.6
HS+PCR1	6.0	4.8	23.5
HS+PCR2	6.0	4.8	23.5
HS+PCR3	6.0	4.7	23.5

Health screening only: HR, Health screening combined with PCR testing at a detection limit of 10 copies/mL: HS+PCR1, 250 copies/mL: HS+PCR2, 1000 copies/mL: HS+PCR3.

544